Solid Tumor Therapeutic Market by Therapy Types (Chemotherapy, Hormone Therapy, Immunotherapy, and Targeted Therapy), Applications (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global solid tumor therapeutic market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising incidence of cancer and increasing awareness about cancer through government initiatives.
Solid tumors are formed by aggregation of abnormal tissues that do not contain any liquid or cyst. These solid tumors are of two types namely benign and malignant. The treatment of these solid tumors is tough and it requires synchronized actions of healthcare professionals, such as surgeons, radiologists, radiation specialists, and oncologists. Most of the solid tumors are treated through chemotherapy, radiotherapy, and surgery.
Surgery is the most appropriate treatment for cancer tumors. Chemotherapy is frequently used along with other types of solid tumor therapeutics. Solid tumor therapeutics are pharmaceutical products that specifically treat various cancers such as lung cancer, breast cancer, prostate cancer, colorectal cancer, and cervical cancer. For oncology treatments, solid tumor therapeutics has come out as an effective anti-cancer therapy. Most common forms of solid tumors include neuroblastoma and brain tumors (glioma and medulloblastoma), while rare solid tumors include osteosarcoma and rhabdomyosarcoma.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing number of product approvals for ovarian, pancreatic, and prostate cancer treatment is projected to boost the market growth.
- Rising incidence of solid tumor among cancer patients and growing prevalence of metastatic cancers are some of the major factors that are expected to drive the market growth.
- Growing development of biosimilars is one of the emerging trends that is fueling the market growth during forecast period.
- Rising investment in clinical trials, increasing expenditure on cancer treatment, and unfulfilled demand for effective cancer treatment drugs are key factors, which are expected to foster the global solid tumor therapeutics market growth.
- High cost of cancer therapy and increasing volume of generic therapeutic products are anticipated to hamper the market growth in coming years.
- Stringent regulatory reforms may hinder the growth of this market.
- Increasing R&D investment and technological advancements in treatment techniques, such as targeted and combination therapies can create significant opportunities for the market players during the forecast period.
Scope of the Report
The report on the global solid tumor therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Solid Tumor Therapeutic Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Therapy Types (Chemotherapy, Hormone Therapy, Immunotherapy, and Targeted Therapy) and Applications (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Abbott Laboratories Inc., Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, and GlaxoSmithKline PLC |
Solid Tumor Therapeutic Market Segment Insights
Chemotherapy segment to grow at a significant pace
Based on therapy types, the market is classified as chemotherapy, hormone therapy, immunotherapy, and targeted therapy. The chemotherapy segment is expected to expand at rapid pace due to availability of its generic version at affordable cost, which increases its preference for treating cancer. This therapy can be used to treat tumors with combination drugs.
Breast cancer segment to hold a major market Share
In terms of applications, the market is divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and others. The breast cancer segment is projected to hold a major market share owing to increasing hormonal imbalance during the menstrual cycle, unhealthy lifestyle, and decreased breastfeeding to infants. However, the lung cancer segment is anticipated to expand at a rapid pace during the forecast period owing to rising number of smokers and increasing air pollution.
North America to dominate the market
On the basis of regions, the market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during forecast period owing to rising incidence rate of cancer, rising awareness among people, and rapid development healthcare infrastructure in countries such as the US and Canada.
Segments
Segments Covered in the Report
The global solid tumor therapeutic market has been segmented on the basis of
Therapy Types
- Chemotherapy
- Hormone Therapy
- Immunotherapy
- Targeted Therapy
Applications
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Abbott Laboratories Inc.
- Amgen Inc.
- AstraZeneca PLC
- Hoffmann-La Roche AG
- GlaxoSmithKline PLC
Competitive Landscape
Key players competing in the solid tumor therapeutic market are Abbott Laboratories Inc.; Amgen Inc.; AstraZeneca PLC; F. Hoffmann-La Roche AG; and GlaxoSmithKline PLC.
The rising need for cancer treatment and increasing prevalence of cancer, entry of a few smaller plaayers in the market is expected.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Solid Tumor Therapeutic Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Solid Tumor Therapeutic Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Solid Tumor Therapeutic Market - Supply Chain
4.5. Global Solid Tumor Therapeutic Market Forecast
4.5.1. Solid Tumor Therapeutic Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Solid Tumor Therapeutic Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Solid Tumor Therapeutic Market Absolute $ Opportunity
5. Global Solid Tumor Therapeutic Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Solid Tumor Therapeutic Market Size and Volume Forecast by Applications
5.3.1. Breast Cancer
5.3.2. Lung Cancer
5.3.3. Colorectal Cancer
5.3.4. Prostate Cancer
5.3.5. Cervical Cancer
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Solid Tumor Therapeutic Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Solid Tumor Therapeutic Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Solid Tumor Therapeutic Demand Share Forecast, 2019-2026
7. North America Solid Tumor Therapeutic Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Solid Tumor Therapeutic Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Solid Tumor Therapeutic Market Size and Volume Forecast by Applications
7.4.1. Breast Cancer
7.4.2. Lung Cancer
7.4.3. Colorectal Cancer
7.4.4. Prostate Cancer
7.4.5. Cervical Cancer
7.4.6. Others
7.5. Basis Point Share (BPS) Analysis by Applications
7.6. Y-o-Y Growth Projections by Applications
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Solid Tumor Therapeutic Demand Share Forecast, 2019-2026
8. Latin America Solid Tumor Therapeutic Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Solid Tumor Therapeutic Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Solid Tumor Therapeutic Market Size and Volume Forecast by Applications
8.4.1. Breast Cancer
8.4.2. Lung Cancer
8.4.3. Colorectal Cancer
8.4.4. Prostate Cancer
8.4.5. Cervical Cancer
8.4.6. Others
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Solid Tumor Therapeutic Demand Share Forecast, 2019-2026
9. Europe Solid Tumor Therapeutic Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Solid Tumor Therapeutic Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Solid Tumor Therapeutic Market Size and Volume Forecast by Applications
9.4.1. Breast Cancer
9.4.2. Lung Cancer
9.4.3. Colorectal Cancer
9.4.4. Prostate Cancer
9.4.5. Cervical Cancer
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Solid Tumor Therapeutic Demand Share Forecast, 2019-2026
10. Asia Pacific Solid Tumor Therapeutic Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Solid Tumor Therapeutic Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Solid Tumor Therapeutic Market Size and Volume Forecast by Applications
10.4.1. Breast Cancer
10.4.2. Lung Cancer
10.4.3. Colorectal Cancer
10.4.4. Prostate Cancer
10.4.5. Cervical Cancer
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Solid Tumor Therapeutic Demand Share Forecast, 2019-2026
11. Middle East & Africa Solid Tumor Therapeutic Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Solid Tumor Therapeutic Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Solid Tumor Therapeutic Market Size and Volume Forecast by Applications
11.4.1. Breast Cancer
11.4.2. Lung Cancer
11.4.3. Colorectal Cancer
11.4.4. Prostate Cancer
11.4.5. Cervical Cancer
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Solid Tumor Therapeutic Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Solid Tumor Therapeutic Market: Market Share Analysis
12.2. Solid Tumor Therapeutic Distributors and Customers
12.3. Solid Tumor Therapeutic Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Abbott Laboratories Inc.
12.4.2. Amgen Inc.
12.4.3. AstraZeneca PLC
12.4.4. Hoffmann-La Roche AG
12.4.5. GlaxoSmithKline PLC
Segments Covered in the Report
The global solid tumor therapeutic market has been segmented on the basis of
Therapy Types
- Chemotherapy
- Hormone Therapy
- Immunotherapy
- Targeted Therapy
Applications
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Abbott Laboratories Inc.
- Amgen Inc.
- AstraZeneca PLC
- Hoffmann-La Roche AG
- GlaxoSmithKline PLC
Key players competing in the solid tumor therapeutic market are Abbott Laboratories Inc.; Amgen Inc.; AstraZeneca PLC; F. Hoffmann-La Roche AG; and GlaxoSmithKline PLC.
The rising need for cancer treatment and increasing prevalence of cancer, entry of a few smaller plaayers in the market is expected.
Our Clients
Related Reports
Some other reports from this category!
